| Project/Area Number |
11671671
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kobe University Graduate School of Medicine (2001)
The University of Tokyo (1999-2000) |
|---|
Principal Investigator |
NIBU Ken-ichi Kobe University Graduate School of Medicine Professor, 大学院・医学系研究科, 教授 (20251283)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIMIZU Ken-ichiro Kobe University University Hospital Attending, 医学部附属病院, 助手 (00335431)
OHTSU Masanide Kobe University Graduate School of Medicine Attending, 大学院・医学系研究科, 助手 (50283883)
ISHIDA Haruhiko Kobe University Graduate School of Medicine Associate Professor, 大学院・医学系研究科, 助教授 (70223005)
菅澤 正 (管澤 正) 東京大学, 医学部・附属病院分院, 助教授 (00179110)
石橋 敏夫 東京大学, 医学部・附属病院・分院, 講師 (50212923)
|
|---|
| Project Period (FY) |
1999 – 2002
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 2001: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2000: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1999: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | Thyroid / papillary carcinoma / ret / p53 / papillary carcinoma / ras / PTC / thyroid / papillary / carcinoma |
|---|
| Research Abstract |
Background: The activation of ret proto-oncogene, through chromosomal translocation, is reported as unique to papillary thyroid carcinomas. However, the prevalence of RET/PTC activation in papillary carcinoma reported was variable and the clinical relevance of RET/PTC rearrangements in papillary carcinomas is still controversial.
Methods: To investigate the roles of ret rearrangement in the carcinogenesis of papillary thyroid carcinoma, we have studied ret activation and p53 overexpression in various thyroid lesions of Japanese population by immunohistochemical technique.
Results: Ret activation and p53 overexpression were studied in 40 papillary carcinomas, 5 poorly differentiated carcinomas, 1 undifferentiated carcinoma, 2 medullary carcinoma, 2 follicular carcinomas, 19 follicular adenomas. RET activation was observed in 12 out of 40 papillary carcinomas, while no immunoreactivity of ret was detected in other lesions. P53 overexpression was observed in only one of 40 papillary carcinomas.
Conclusion: The prevalence of RET/PTC activation in papillary carcinoma among Japanese population was higher than previous reports. Immunohistochemistry is proved as a useful tool to detect RET/PTC activation in thyroid tumors. RET rearrangements are restricted to a well-differentiated papillary carcinoma, suggesting that RET/PTC positive papillary carcinomas do not progress to undifferentiated carcinoma.
|
